Analysis of Proteome and Pathophysiological Characteristics of Human Blood Cells

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02272530

Enrollment

200

Registered

2014-10-23

Start date

2012-07-31

Completion date

2020-12-31

Last updated

2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial NO-synthase, Peripheral Blood Mononuclear Cell, Red Blood Cell

Keywords

Endothelial NO-synthase, red blood cell, erythrocytes, Peripheral Blood Mononuclear Cell, cardiovascular disease

Brief summary

The aim of this study is to investigate wether change in endothelial nitric oxid synthase of blood cells (erythrocytes and peripheral blood mononuclear cells (PBMC)) has an influence on development and progression of cardiovascular diseases.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy volunteers * Patients: stable coronary artery disease with accordingly endothelial dysfunction

Exclusion criteria

* acute inflammation (CRP\>0,5 mg/dl, leucocyte \>11000/dl) * malignant diseases * acute or terminated kidney disease * relevant heart failure (NYHA III-IV)

Design outcomes

Primary

Measure	Time frame	Description
Blood examination	baseline	Following parameters will be examined: * Blood count (red cells, white cells, platelets, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width (RDW), mean platelet volume (MPV) ) * Creatinin * Urea * Glucose * Glycated hemoglobin (HbA1c) * Cholesterol * Triglyceride * C-reactive Protein * Apolipoprotein

Secondary

Measure	Time frame	Description
Asymmetric dimethylarginine (ADMA) and Cytokine	baseline	Determination with enzyme-linked immunosorbent assay (ELISA).
Microparticles	baseline	Determination with ELISA and flow cytometry
Protein expression	baseline	Determination with western blot
Nitric oxid metabolite and proteins in blood plasma, red blood cells and peripheral blood mononuclear cells (PBMN)	baseline	Determination with reductive chemiluminescence
Nitric oxid and reactive oxygen species	baseline	Determination with fluorescence coloring in flow cytometry and fluorescence microscopy
Immunocytochemistry	baseline	—

Countries

Germany

Outcome results